MedTrace Logo

Erinacine A-enriched Hericium Erinaceus Mycelia for Improvement of Recognition, Vision, and Functional MRI Alterations

NCT04065061 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2019-08-22

No results posted yet for this study

Summary

This study was designed as randomized double blind placebo study to investigate the efficacy of Erinacine A-enriched Hericium erinaceus mycelia for improvement of recognition, vision, and functional MRI alterations.

Conditions

  • Supplement
  • Cognition Disorders in Old Age
  • Vision
  • fMRI

Interventions

DIETARY_SUPPLEMENT

Erinacine A-enriched Hericium Erinaceus Mycelia

DIETARY_SUPPLEMENT

Placebo

Placebo supplement was given to the participants.

Sponsors & Collaborators

  • Grape King Bio Ltd.

    collaborator INDUSTRY

  • Chung Shan Medical University

    lead OTHER

Principal Investigators

  • David Pei-Cheng Lin, PhD · Chung Shan Medical University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-22
Primary Completion
2016-05-10
Completion
2017-05-10

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04065061 on ClinicalTrials.gov